<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02895048</url>
  </required_header>
  <id_info>
    <org_study_id>ID CP OPT2009-007</org_study_id>
    <nct_id>NCT02895048</nct_id>
  </id_info>
  <brief_title>Effects of CCM-therapy in Patients With Heart Failure</brief_title>
  <acronym>CCM-HF</acronym>
  <official_title>Clinical Effects of Cardiac Contractility Modulation (CCM) With the OPTIMIZER III System in Subjects With Heart Failure Caused by Left Ventricular Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stiftung Institut fuer Herzinfarktforschung</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Impulse Dynamics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stiftung Institut fuer Herzinfarktforschung</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effects of Cardiac Contractility Modulation (CCM) treatment are observed in patients with&#xD;
      heart failure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The OPTIMIZER III System is indicated for use in patients greater than 18 years of age with&#xD;
      symptomatic heart failure due to left ventricular systolic dysfunction despite appropriate&#xD;
      medical therapy. The study will gather additional data on the effect of CCM treatment with&#xD;
      the objective of determining the impact of CCM on the composite of heart failure&#xD;
      hospitalizations and mortality in the low ejection fraction (EF &lt; 35%) and mildly reduced&#xD;
      ejection fraction (35 ≤ EF ≤ 45) heart failure population. The study will also assess the&#xD;
      impact of CCM on exercise tolerance (six minute hall walk test, 6 Minute Walk Test) and&#xD;
      quality of life (Minnesota Living With Heart Failure Questionnaire, MLWHFQ) in these same&#xD;
      populations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause and cardiac mortality</measure>
    <time_frame>24 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the rate of all-cause and cardiac-related hospitalizations</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">184</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Chronic heart failure</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>CCM treatment</arm_group_label>
    <description>Subjects with heart failure receiving OPTIMIZER system implant</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study shall include up to 300 subjects with CCM treatment and up to 300 subjects&#xD;
        without CCM treatment. Patients without CCM treatment serve as Control patients and they&#xD;
        will be recruited from centers not implanting OPTIMIZER systems.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria (treatment group):&#xD;
&#xD;
          -  Any subject who receives an OPTIMIZER system implant and provides informed consent&#xD;
&#xD;
        Exclusion Criteria (treatment group):&#xD;
&#xD;
          -  None&#xD;
&#xD;
        Inclusion Criteria (control group):&#xD;
&#xD;
          -  Symptomatic heart failure (NYHA Class 2, 3 or 4) despite receiving optimal medical&#xD;
             therapy with doses of medications that are stable (no more than 50 % variation) for at&#xD;
             least 7 days.&#xD;
&#xD;
          -  EF ≤ 45%&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria (control group):&#xD;
&#xD;
          -  Heart failure due to a potentially correctible cause ( e. g. valvular disease,&#xD;
             congenital disease)&#xD;
&#xD;
          -  Idiopathic hypertrophic cardiomyopathy, restrictive or constrictive cardiomyopathy, or&#xD;
             heart failure on the basis of a known inflammatory or infiltrative disease (e. g.&#xD;
             amyloidosis, sarcoidosis) or constrictive disease&#xD;
&#xD;
          -  Active ischemia or exercise tolerance limited by angina&#xD;
&#xD;
          -  Hospitalizations for heart failure which required the use of inotropic support within&#xD;
             14 days of enrollment&#xD;
&#xD;
          -  Chronic (permanent or persistent) atrial fibrillation or atrial flutter&#xD;
&#xD;
          -  Scheduled for a CABG or a PCI procedure, or has undergone a CABG procedure within 90&#xD;
             days or a PCI procedure within 30 days of enrollment&#xD;
&#xD;
          -  Myocardial infarction within 90 days of enrollment&#xD;
&#xD;
          -  Hemodialysis or peritoneal dialysis&#xD;
&#xD;
          -  Prior heart transplant&#xD;
&#xD;
          -  Participating in another study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Remppis, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bad Bevensen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CCB</name>
      <address>
        <city>Frankfurt/Main</city>
        <state>Hesse</state>
        <zip>29549</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>October 7, 2011</study_first_submitted>
  <study_first_submitted_qc>September 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2016</study_first_posted>
  <last_update_submitted>September 5, 2016</last_update_submitted>
  <last_update_submitted_qc>September 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

